- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02412098
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
May 31, 2019 updated by: Gilead Sciences
A Phase 1, Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic function.
Participants in the healthy control group will be matched to participants with impaired hepatic function by age (± 5 years), gender, and body mass index (± 10%).
Study Overview
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
München, Germany
-
-
-
-
-
Auckland, New Zealand
-
-
-
-
-
Bucharest, Romania
-
-
-
-
Florida
-
Miami, Florida, United States
-
Orlando, Florida, United States
-
-
Minnesota
-
Minneapolis, Minnesota, United States
-
-
Missouri
-
Kansas City, Missouri, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All participants:
- Be a nonsmoker or consume < 20 cigarettes per day
- Have a calculated body mass index (BMI) from 18 to 36 kg/m^2, inclusive, at study screening
- Have a creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at screening
- Have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that are considered clinically insignificant by the investigator
- Screening labs within defined thresholds
Participants with mild, moderate, or severe hepatic impairment must also meet the following additional inclusion criteria:
- Must have diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically significant changes within 3 months (90 days) prior to study drug administration (Day 1)
- Individuals with severe hepatic impairment must have a score on the Child-Pugh-Turcotte scale of 10-15 at screening. If an individual's score changes during the course of the study, the score at screening will be used for classification.
- Individuals with moderate hepatic impairment must have a score on the Child-Pugh-Turcotte scale of 7-9 at screening. If an individual's score changes during the course of the study, the score at Screening will be used for classification.
- Individuals with mild hepatic impairment must have a score on the Child-Pugh-Turcotte scale of 5-6 at screening. If an individual's score changes during the course of the study, the score at screening will be used for classification.
Exclusion Criteria:
- Pregnant or lactating females
- History of meningitis or encephalitis, epilepsy, seizures, migraines, tremors, myoclonic jerks, narcolepsy, obstructive sleep apnea, anxiety, syncope, head injuries or a family history of seizures
- Presence or history of cardiovascular disease (including history of myocardial infarction based on ECG and/or clinical history, any history of ventricular tachycardia, congestive heart failure, cardiomyopathy, or left ventricular ejection fraction < 40%), cardiac conduction abnormalities, a family history of Long QT Syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years
- Syncope, palpitations, or unexplained dizziness
- Implanted defibrillator or pacemaker
- Are unable to comply with study requirements or are otherwise believed, by the study investigator, to be inappropriate for study participation for any reason
Participants with mild, moderate, or severe hepatic impairment must also meet the following additional exclusion criteria:
- Active hepatitis B virus (HBV) infection. Individuals who have HBsAg are ineligible
- Requires paracentesis > 1 time per month
- Severe (grade 3 or 4) encephalopathy as judged by the investigator
- History of gastric or esophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated with medication and/or surgical procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Moderate Hepatic Impairment (Cohort 1)
Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
|
Eleclazine tablets administered orally
Other Names:
|
Experimental: Severe Hepatic Impairment (Cohort 2)
Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
|
Eleclazine tablets administered orally
Other Names:
|
Experimental: Mild Hepatic Impairment (Cohort 3)
Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
|
Eleclazine tablets administered orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK (Pharmacokinetic) Parameter: AUCinf of Eleclazine
Time Frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).
|
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
PK Parameter: AUCinf of GS-623134 (Metabolite of Eleclazine)
Time Frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).
|
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
PK Parameter: Cmax of Eleclazine
Time Frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
Cmax was defined as the maximum observed concentration of drug in plasma.
|
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
PK Parameter: Cmax of GS-623134 (Metabolite of Eleclazine)
Time Frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
Cmax was defined as the maximum observed concentration of drug in plasma.
|
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing Treatment-Emergent Adverse Events
Time Frame: First dose date up to 31 days
|
Treatment-emergent adverse events (AEs) are defined as one or both of the following:
|
First dose date up to 31 days
|
Number of Participants Experiencing Clinical Laboratory Abnormalities
Time Frame: First dose date up to 31 days
|
Treatment-emergent laboratory abnormalities reported as an adverse event (AE) or serious adverse event (SAE) are presented.
Laboratory abnormalities that required medical or surgical intervention or led to study drug interruption, modification, or discontinuation were recorded as an AE or SAE, as applicable, and are reported here.
Laboratory abnormalities without clinical significance were not recorded as AEs or SAEs and therefore, are not being reported.
|
First dose date up to 31 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 19, 2015
Primary Completion (Actual)
April 22, 2016
Study Completion (Actual)
April 22, 2016
Study Registration Dates
First Submitted
March 11, 2015
First Submitted That Met QC Criteria
April 3, 2015
First Posted (Estimate)
April 8, 2015
Study Record Updates
Last Update Posted (Actual)
July 29, 2019
Last Update Submitted That Met QC Criteria
May 31, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-US-372-1048
- 2014-005266-30 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Long QT Syndrome
-
Nantes University HospitalUnknownLong QT Syndrome Type 1 or 2France
-
Herlev and Gentofte HospitalCompletedSudden Cardiac Death | Long Qt Syndrome 1-2Denmark
-
Gilead SciencesCompleted
-
Gilead SciencesTerminatedLong QT Syndrome Type 3United States, Germany, Canada, Netherlands, Italy, France, Israel, United Kingdom
-
Tel-Aviv Sourasky Medical CenterUnknownLong QT Syndrome Type 3Israel
-
Massachusetts General HospitalBoston University; Mayo Clinic; Beth Israel Deaconess Medical Center; The Cleveland... and other collaboratorsTerminatedLong qt Syndrome | Torsade de PointesUnited States
-
University Hospital, MontpellierInstitut National de la Santé Et de la Recherche Médicale, FranceActive, not recruitingPediatric ALL | Long QT Syndrome | Inherited Cardiac Conduction Disorder | Congenital Long Qt SyndromeFrance
-
KU LeuvenAgentschap voor Innovatie door Wetenschap en TechnologieCompleted
-
KU LeuvenAgentschap voor Innovatie door Wetenschap en TechnologieCompleted
-
NorthShore University HealthSystemUnknownEKG-QT ProlongationUnited States
Clinical Trials on Eleclazine
-
Gilead SciencesTerminatedLong QT Syndrome Type 3United States, Germany, Canada, Netherlands, Italy, France, Israel, United Kingdom
-
Gilead SciencesCompletedVentricular ArrhythmiaNetherlands, Israel, United States, Denmark, Canada, Germany, Czechia, Hungary, Poland
-
Gilead SciencesCompletedLong QT SyndromeUnited States, Romania, Moldova, Republic of
-
Gilead SciencesTerminatedHypertrophic CardiomyopathyAustralia, United States, Netherlands, Israel, Italy, France, Germany, United Kingdom
-
Gilead SciencesCompleted
-
National and Kapodistrian University of AthensUniversity of Oxford; Naval Hospital of Athens; Biomedical Research Foundation...RecruitingAortic Valve Stenosis | Calcific Aortic Valve Disease | Aortic Valve, Calcification ofGreece
-
Universidad Autonoma de Nuevo LeonCompletedPlantar Fascitis | Botulinum Toxins, Type AMexico